JP2020169191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020169191A5 JP2020169191A5 JP2020106978A JP2020106978A JP2020169191A5 JP 2020169191 A5 JP2020169191 A5 JP 2020169191A5 JP 2020106978 A JP2020106978 A JP 2020106978A JP 2020106978 A JP2020106978 A JP 2020106978A JP 2020169191 A5 JP2020169191 A5 JP 2020169191A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- pharmaceutical composition
- additional
- interval
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022076645A JP2022107628A (ja) | 2013-11-05 | 2022-05-06 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900246P | 2013-11-05 | 2013-11-05 | |
| US61/900,246 | 2013-11-05 | ||
| US201462016620P | 2014-06-24 | 2014-06-24 | |
| US62/016,620 | 2014-06-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552455A Division JP2016536369A (ja) | 2013-11-05 | 2014-11-04 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022076645A Division JP2022107628A (ja) | 2013-11-05 | 2022-05-06 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020169191A JP2020169191A (ja) | 2020-10-15 |
| JP2020169191A5 true JP2020169191A5 (https=) | 2021-02-25 |
Family
ID=51947485
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552455A Pending JP2016536369A (ja) | 2013-11-05 | 2014-11-04 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
| JP2020106978A Pending JP2020169191A (ja) | 2013-11-05 | 2020-06-22 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
| JP2022076645A Pending JP2022107628A (ja) | 2013-11-05 | 2022-05-06 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552455A Pending JP2016536369A (ja) | 2013-11-05 | 2014-11-04 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022076645A Pending JP2022107628A (ja) | 2013-11-05 | 2022-05-06 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20150126458A1 (https=) |
| EP (2) | EP3628324A1 (https=) |
| JP (3) | JP2016536369A (https=) |
| KR (1) | KR20160070164A (https=) |
| CN (1) | CN105960247A (https=) |
| AU (2) | AU2014346921A1 (https=) |
| CA (1) | CA2927012A1 (https=) |
| DK (1) | DK3065761T3 (https=) |
| ES (1) | ES2773317T3 (https=) |
| HU (1) | HUE047910T2 (https=) |
| PL (1) | PL3065761T3 (https=) |
| PT (1) | PT3065761T (https=) |
| TW (1) | TWI729970B (https=) |
| WO (1) | WO2015069668A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007237096C1 (en) | 2006-04-07 | 2012-12-13 | EyePoint, Inc. | Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof |
| AU2012323856B2 (en) | 2011-10-13 | 2017-05-25 | EyePoint, Inc. | Methods for treating Vascular Leak Syndrome and cancer |
| HUE046134T2 (hu) | 2012-05-07 | 2020-02-28 | Allergan Inc | Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben |
| US11103552B2 (en) | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
| CN120058958A (zh) | 2018-09-24 | 2025-05-30 | 视点制药公司 | 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体 |
| SG11202112925PA (en) * | 2019-06-04 | 2021-12-30 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| CN118718181A (zh) | 2019-06-05 | 2024-10-01 | 里珍纳龙药品有限公司 | 用于精确剂量递送的装置及方法 |
| AU2021356298A1 (en) * | 2020-10-07 | 2023-05-04 | Line 6 Biotechnology, Inc | Methods and agents for the treatment of ocular disease |
| CA3197759A1 (en) * | 2020-10-08 | 2022-04-14 | Notal Vision Ltd. | Oct guided therapy |
| CN114075290B (zh) * | 2022-01-20 | 2022-04-19 | 南京鼓楼医院 | Cd40靶向结合蛋白、其编码核酸以及用途 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100523187C (zh) | 1999-06-08 | 2009-08-05 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| DE60140474D1 (de) | 2000-09-08 | 2009-12-24 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| EP1996937A4 (en) | 2006-03-06 | 2009-04-08 | Amunix Inc | GENETIC PACKS AND USES THEREOF |
| US20100144599A1 (en) | 2007-02-02 | 2010-06-10 | Bristol-Myers Squibb Company | Vegf pathway blockade |
| ATE502114T1 (de) | 2007-06-21 | 2011-04-15 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| EP3785735A1 (en) | 2008-11-03 | 2021-03-03 | Molecular Partners AG | Binding proteins inhibiting the vegf-a receptor interaction |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| HUE046134T2 (hu) * | 2012-05-07 | 2020-02-28 | Allergan Inc | Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben |
-
2014
- 2014-11-04 CA CA2927012A patent/CA2927012A1/en not_active Abandoned
- 2014-11-04 PL PL14802544T patent/PL3065761T3/pl unknown
- 2014-11-04 US US14/532,397 patent/US20150126458A1/en not_active Abandoned
- 2014-11-04 HU HUE14802544A patent/HUE047910T2/hu unknown
- 2014-11-04 PT PT148025448T patent/PT3065761T/pt unknown
- 2014-11-04 AU AU2014346921A patent/AU2014346921A1/en not_active Abandoned
- 2014-11-04 CN CN201480060463.5A patent/CN105960247A/zh active Pending
- 2014-11-04 EP EP19192065.1A patent/EP3628324A1/en not_active Withdrawn
- 2014-11-04 ES ES14802544T patent/ES2773317T3/es active Active
- 2014-11-04 DK DK14802544.8T patent/DK3065761T3/da active
- 2014-11-04 EP EP14802544.8A patent/EP3065761B1/en active Active
- 2014-11-04 JP JP2016552455A patent/JP2016536369A/ja active Pending
- 2014-11-04 KR KR1020167014741A patent/KR20160070164A/ko not_active Ceased
- 2014-11-04 WO PCT/US2014/063951 patent/WO2015069668A1/en not_active Ceased
- 2014-11-05 TW TW103138456A patent/TWI729970B/zh not_active IP Right Cessation
-
2016
- 2016-08-05 US US15/230,244 patent/US20170157207A1/en not_active Abandoned
-
2020
- 2020-01-31 US US16/778,290 patent/US20210008158A1/en not_active Abandoned
- 2020-05-05 AU AU2020202968A patent/AU2020202968A1/en not_active Abandoned
- 2020-06-22 JP JP2020106978A patent/JP2020169191A/ja active Pending
-
2021
- 2021-10-13 US US17/500,315 patent/US20220175881A1/en not_active Abandoned
-
2022
- 2022-05-06 JP JP2022076645A patent/JP2022107628A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020169191A5 (https=) | ||
| TWI816739B (zh) | 包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑 | |
| CN104507492B (zh) | 治疗高脂血症的包含泌酸调节肽衍生物的组合物 | |
| JP2016536369A5 (https=) | ||
| US10130688B2 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| Bansal et al. | Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo | |
| JP2010500399A5 (https=) | ||
| JP2017538395A5 (https=) | ||
| JP2016512213A5 (https=) | ||
| JP2014521684A5 (https=) | ||
| RU2012151205A (ru) | Модифицированные связывающие белки, ингибирующие взаимодействие vegf-a рецептора | |
| US20180327473A1 (en) | Human Alpha Fetoprotein-Specific Murine T Cell Receptors and Uses Thereof | |
| JP2014502252A5 (https=) | ||
| CN102917726A (zh) | 干扰素类似物 | |
| CN105263957A (zh) | 治疗肽 | |
| CA2752608A1 (en) | Cytotoxic conjugates having neuropeptide y receptor binding compound | |
| US10815286B2 (en) | Fusion protein for treating intestinal diseases | |
| JP2009520758A5 (https=) | ||
| US20230399364A1 (en) | Immunogenic Coronavirus Fusion Proteins and Related Methods | |
| CN105229025A (zh) | 位点特异性胰岛素缀合物 | |
| JP2020527556A5 (https=) | ||
| JP2004533250A5 (https=) | ||
| US20190358313A1 (en) | New flavivirus vaccine | |
| Mezo | Peptide and protein based pharmaceuticals | |
| JP2020504081A5 (https=) |